

Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification on 26 February 2015 that AXA S.A.'s holding has fallen below the disclosure threshold of 3%.

Based on the denominator of 31,431,360 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:

	Number of shares	% of effective voting rights
Carmignac Gestion	2,463,267	7.84%
TIAA-CREF Asset Management LLC	1,635,681	5.22%
BNP Paribas Investment Partners SA	1,609,182	5.13%
Fidelity Management and Research (FMR LLC)	1,573,158	5.01%

The original notification forms are available on the website investors.fagron.com.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organisation consists of more than 300 pharmacists who are working continually on developing new formulations to treat an increasing number of patients with customised compounded medication.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com

¹ This press release was sent out by Fagron NV and Fagron BV.

